The Heart Rhythm Society just wrapped up its four-day Heart Rhythm 2025 conference at the San Diego Convention Center on April 27. With over 7,000 attendees and 200 sessions presented by leading healthcare experts, the conference was the largest educational program for heart rhythm professionals in the world.
Unsurprisingly, such a unique event was the source of some exciting revelations in heart care. The following are some highlights from Heart Rhythm 2025.
Heart Rhythm 2025 Showcases New Advancements in Emerging Pulsed Field Ablation Technology
The Heart Rhythm 2025 conference featured many eye-opening revelations centering on pulsed field ablation. Many studies were presented on the potential of PFA as a comparably effective and possibly safer alternative to traditional thermal-based catheter ablation for atrial fibrillation.
Kardium Inc’s PULSAR IDE study demonstrated the effectiveness of their Globe® Pulsed Field System: a procedure time averaging 95.8 minutes, with 78% of patients remaining free of paroxysmal atrial fibrillation after 12 months.
The Ventricular Catheter Ablation Study evaluating the FieldForce™ Ablation System saw an ablation time of 35 minutes and fluoroscopy time of 15 minutes. Of a subset of the patients in the study, 78% remained free of ventricular tachycardia following treatment. It was noted that 2 out of 22 patients saw a notable worsening of heart failure.
Results from the Omny-IRE clinical trial showed the OMNYPULSE™ Platform performed well. There was a reported 100% success rate in achieving acute pulmonary vein isolation, with a median time of 105.5 minutes with five minutes of fluoroscopy time.
New Study Finds GLP-1 Receptor Agonists May Reduce Atrial Fibrillation-Related Events in Patients with Obesity
A large study of 2,510 patients from across the United States found that GLP-1 RAs reduced AF-related events by 13%. For patients with severe obesity (BMI over 40), the results were even greater.
Over a median 3-year period, the TRANSFORM-AF study found that GLP-1 RA use was associated with a 13% reduction in major AF-related events, including ablation procedures, cardioversions, and hospitalizations for AF. Only modest weight loss was noted with diabetes management doses. Weight-loss doses could yield greater potential benefits.
Late-Breaking Clinical Trials at Heart Rhythm 2025 Showcase Promising Outcomes for Left Bundle Branch Area Pacing in Heart Failure Treatment
Presented as late-breaking clinical science, researchers from two clinical trials presented their findings that left bundle branch area pacing is effective and safe when compared to biventricular pacing (BVP) for patients undergoing cardiac resynchronization therapy (CRT).
I-CLAS conducted a study of 2,579 international patients undergoing CRT with left ventricular ejection fraction of <50%. Comparing LBBAP to BVP saw notably better outcomes for the former. After a mean follow-up of 34±15 months, LBBAP saw an 8.6% lower rate of death or heart failure hospitalization and a 7.2% lower time to heart failure hospitalization.
Results from the LEADR LBBAP study demonstrated the prospect that the OmniaSecure™ defibrillation lead may eventually be used in areas other than the right ventricular for defibrillation, cardioversion, pacing, and sensing.
For more highlights from this year’s HRS 2025 conference, visit the Heart Rhythm Society’s website.
Sign up for alerts to stay informed on the latest published guidelines and more conference recaps.
Copyright © 2025 Guideline Central, all rights reserved.